Abstract

The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D. Since then, development has been promoted in the direction of introducing preoperative chemotherapy, changing post-operative adjuvant chemotherapy according to histological effects, adding ifosfamide as a key drug and strengthening adjuvant chemotherapy. No clinical trials, however, have shown the effectiveness of study treatment, and the improvement of treatment results during that time has been slight, although the JCOG0905 study is now going to verify the effectiveness of introducing ifosfamide for patients who experienced limited preoperative therapeutic effects. We are desperately looking for a breakthrough.

中文翻译：

---

骨肉瘤的辅助和新辅助化疗：JCOG 骨和软组织肿瘤研究组

摘要

1980 年代进行的两项随机对照试验确定了辅助化疗对高级别骨肉瘤的有效性，这些试验使用了六种药物，阿霉素、顺铂、大剂量甲氨蝶呤、博来霉素、环磷酰胺和放线菌素 D。从那时起，发展推进引入术前化疗、根据组织学效应改变术后辅助化疗、增加异环磷酰胺为重点药物、加强辅助化疗等方向。然而，没有临床试验显示研究治疗的有效性，并且在此期间治疗结果的改善很小，尽管 JCOG0905 研究现在将验证引入异环磷酰胺对术前治疗效果有限的患者的有效性。